Boston Scientific Corporation
BSX · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $17 | $14 | $13 | $12 |
| % Growth | 17.6% | 12.3% | 6.7% | – |
| Cost of Goods Sold | $6 | $5 | $5 | $4 |
| Gross Profit | $10 | $9 | $8 | $7 |
| % Margin | 61.3% | 62% | 60.8% | 62.8% |
| R&D Expenses | $2 | $1 | $1 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $6 | $5 | $5 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8 | $7 | $6 | $6 |
| Operating Income | $3 | $2 | $2 | $2 |
| % Margin | 15.7% | 15.3% | 14.4% | 16.2% |
| Other Income/Exp. Net | -$0 | -$0 | -$1 | -$1 |
| Pre-Tax Income | $2 | $2 | $1 | $1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $2 | $2 | $1 | $1 |
| % Margin | 11.1% | 11.2% | 5.5% | 8.7% |
| EPS | 1.26 | 1.081 | 0.449 | 0.693 |
| % Growth | 16.6% | 140.8% | -35.2% | – |
| EPS Diluted | 1.25 | 1.073 | 0.446 | 0.687 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $4 | $3 | $3 | $3 |
| % Margin | 23.5% | 24.2% | 21.6% | 21.2% |